HC Wainwright Analysts Lower Earnings Estimates for LPTX

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for Leap Therapeutics in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.38) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.91) EPS and FY2029 earnings at ($0.37) EPS.

Several other equities research analysts have also commented on the stock. Robert W. Baird lowered shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $9.00 to $1.25 in a research report on Wednesday, January 29th. Baird R W cut shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th.

Leap Therapeutics Price Performance

Leap Therapeutics stock opened at $0.29 on Monday. The stock’s 50 day moving average price is $0.64 and its 200 day moving average price is $2.14. The company has a market cap of $11.16 million, a PE ratio of -0.15 and a beta of 0.35. Leap Therapeutics has a 1-year low of $0.28 and a 1-year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02.

Hedge Funds Weigh In On Leap Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Prosperity Wealth Management Inc. acquired a new stake in Leap Therapeutics in the fourth quarter valued at $63,000. HighTower Advisors LLC purchased a new stake in shares of Leap Therapeutics in the 3rd quarter worth about $65,000. HB Wealth Management LLC grew its stake in Leap Therapeutics by 103.2% in the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after acquiring an additional 26,150 shares during the last quarter. Jane Street Group LLC purchased a new position in Leap Therapeutics during the 4th quarter valued at about $107,000. Finally, Key Client Fiduciary Advisors LLC raised its position in Leap Therapeutics by 12.2% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after acquiring an additional 39,330 shares during the last quarter. 30.46% of the stock is owned by institutional investors and hedge funds.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.